spacer
home > pmps > winter 2017 > vanishing act
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Vanishing Act

For drugs which are administered orally – like capsules and tablets – the bioavailability of the drug and its effectiveness are dependent on its solubility in gastrointestinal fluids. Approximately 80% of new small molecule drugs emerging from discovery pipelines can be regarded as poorly soluble. It is not only the growing number of new compounds that have this problem, it is also the extent of insolubility.

Different Approaches
There are several approaches that are commonly used to improve the drug solubility in aqueous media:

Chemical Modification
If the drug substance is a weak acid or base, it may then be possible to form a salt with a suitable counter ion. Salts are often more water-soluble than the free acid or base form of the compound. However, this approach is not appropriate for neutral molecules. Also, there is no guarantee that the water solubility of the salt will be markedly greater than the free form of the drug.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Robert Harris is Chief Technical Officer at Juniper Pharma Services and has over 30 years’ experience in the pharma industry. His early career involved technical roles with Warner Lambert and Glaxo Wellcome before spending time in academia as a Research Fellow at the University of Manchester, UK, where he helped develop novel drug delivery systems.
spacer
Robert Harris
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement